Pressemeddelelse fra LEO Pharma
The agreement represents a milestone in the roll-out of LEO Pharma’s 2030 strategy which strengthens the company’s focus on its innovative and core established portfolio for medical dermatology.
The divested portfolio comprises four products within bone disorders/nephrology, dermatology and gynecology: One-Alpha®, Locoid®, Pimafucin®, and Zineryt®. The annual turnover of the portfolio in 2019 amounted to approximately EUR 110 million.
Following the closing, LEO Pharma and Cheplapharm will work closely together to ensure a smooth and effective transition of the products and business.
Kontakt:
LEO Pharma A/S
Trine Juul Wengel, Global External Communication
tewdk@leo-pharma.com
+45 20732037
Cheplapharm
Stephanie Lemke, Treasury & Investor Relations
Stephanie.lemke@cheplapharm.com
+49 3834 3914 – 142
Læs hele pressemeddelelsen på Via Ritzau her: https://via.ritzau.dk/pressemeddelelse/leo-pharma-completes-sale-of-portfolio-of-four-products-to-cheplapharm?releaseId=13606446
** Ovenstående pressemeddelelse er videreformidlet af Ritzau på vegne af tredjepart. Ritzau er derfor ikke ansvarlig for indholdet **
